Skip to main content
SpringerLink
Log in

Multiple Endocrine Neoplasia

  • Chapter
  • First Online:
Principles of Clinical Cancer Genetics

  • 1305 Accesses

Abstract

Several genetic syndromes are associated with multiple endocrine tumors. In this chapter, we focus on Multiple Endocrine Neoplasia (MEN) types 2 and 1. Von Hippel Lindau and Neurofibromatosis will be discussed in other sections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sipple JH (1961) The association of pheochromocytoma with carcinomas of the thyroid gland. Am J Med 31:163–166

    Google Scholar 

  2. Neumann HP et al (2007) Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 357(13):1311–1315

    PubMed  CAS  Google Scholar 

  3. Arighi E, Borrello MG, Sariola H (2005) RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16(4–5):441–467

    PubMed  CAS  Google Scholar 

  4. Kouvaraki MA et al (2005) RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15(6):531–544

    PubMed  CAS  Google Scholar 

  5. Marx SJ (2005) Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5(5):367–375

    PubMed  CAS  Google Scholar 

  6. Santoro M et al (2002) Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963:116–121

    PubMed  CAS  Google Scholar 

  7. Santoro M et al (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267(5196):381–383

    PubMed  CAS  Google Scholar 

  8. Borrello MG et al (1995) RET activation by germline MEN2A and MEN2B mutations. Oncogene 11(11):2419–2427

    PubMed  CAS  Google Scholar 

  9. Michiels FM et al (1997) Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci USA 94(7):3330–3335

    PubMed  CAS  Google Scholar 

  10. Smith-Hicks CL et al (2000) C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO J 19(4):612–622

    PubMed  CAS  Google Scholar 

  11. Elisei R et al (2004) Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab 89(11):5823–5827

    PubMed  CAS  Google Scholar 

  12. Ito T et al (1994) Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 344(8917):259

    PubMed  CAS  Google Scholar 

  13. Nikiforov YE et al (1997) Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57(9):1690–1694

    PubMed  CAS  Google Scholar 

  14. Nakashima M et al (2007) RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. Hum Pathol 38(4):621–628

    PubMed  CAS  Google Scholar 

  15. Angrist M et al (1995) Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet 4(5):821–830

    PubMed  CAS  Google Scholar 

  16. Edery P et al (1994) Mutations of the RET proto-oncogene in Hirschsprung’s disease. Nature 367(6461):378–380

    PubMed  CAS  Google Scholar 

  17. Romeo G et al (1994) Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung’s disease. Nature 367(6461):377–378

    PubMed  CAS  Google Scholar 

  18. Schuchardt A et al (1994) Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367(6461):380–383

    PubMed  CAS  Google Scholar 

  19. Machens A et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349(16):1517–1525

    PubMed  CAS  Google Scholar 

  20. Brandi ML et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12): 5658–5671

    PubMed  CAS  Google Scholar 

  21. Yip L et al (2003) Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138((4):409–416, discussion 416

    Google Scholar 

  22. Kloos RT et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6):565–612

    PubMed  Google Scholar 

  23. Shaha AR et al (2006) Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members. Laryngoscope 116(9):1704–1707

    PubMed  Google Scholar 

  24. Lesueur F et al (2005) Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients. J Clin Endocrinol Metab 90(6):3454–3457

    PubMed  CAS  Google Scholar 

  25. Costante G et al (2009) Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 5(1):35–44

    PubMed  CAS  Google Scholar 

  26. Schwartz KE et al (1979) Calcitonin in nonthyroidal cancer. J Clin Endocrinol Metab 49(3):438–444

    PubMed  CAS  Google Scholar 

  27. de Groot JW et al (2006) Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid 16(11):1163–1170

    PubMed  Google Scholar 

  28. Laure Giraudet A et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158(2):239–246

    PubMed  Google Scholar 

  29. Mahler C et al (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 33(2):261–269

    CAS  Google Scholar 

  30. Ye L, Santarpia L, Gagel RF (2009) Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm. Endocr Pract 1–24

    Google Scholar 

  31. Carlomagno F et al (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62(24):7284–7290

    PubMed  CAS  Google Scholar 

  32. Hong D et al (2008) Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7(5):1001–1006

    PubMed  CAS  Google Scholar 

  33. Kelleher FC, McDermott R (2008) Response to sunitinib in medullary thyroid cancer. Ann Intern Med 148(7):567

    PubMed  Google Scholar 

  34. Elisei R et al (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92(12):4725–4729

    PubMed  CAS  Google Scholar 

  35. Moura MM et al (2009) Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100(11):1777–1783

    PubMed  CAS  Google Scholar 

  36. Elisei R et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93(3):682–687

    PubMed  CAS  Google Scholar 

  37. Cardot-Bauters C et al (2008) Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma? Clin Endocrinol (Oxf) 69(3):506–510

    CAS  Google Scholar 

  38. Robledo M et al (2003) Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 63(8):1814–1817

    PubMed  CAS  Google Scholar 

  39. Elisei R et al (2004) RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 89(7): 3579–3584

    PubMed  CAS  Google Scholar 

  40. Da Silva AM et al (2003) A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88(11): 5438–5443

    PubMed  Google Scholar 

  41. Howe JR, Norton JA, Wells SA Jr (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 114(6):1070–1077

    PubMed  CAS  Google Scholar 

  42. Nakamura E, Kaelin WG Jr (2006) Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr Pathol 17(2):97–106

    PubMed  CAS  Google Scholar 

  43. Erlic Z, Neumann HP (2009) Familial pheochromocytoma. Hormones (Athens) 8(1):29–38

    Google Scholar 

  44. Machens A et al (2005) Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90(7):3999–4003

    PubMed  CAS  Google Scholar 

  45. Waguespack SG (2009) A perspective from pediatric endocrinology on the hereditary medullary thyroid carcinoma syndromes. Thyroid 19(6):543–546

    PubMed  Google Scholar 

  46. Brauckhoff M, Gimm O (2009) Extrathyroidal manifestations of multiple endocrine neoplasia type 2. Thyroid 19(6):555–557

    PubMed  Google Scholar 

  47. Kinlaw WB et al (2005) Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 63(6):676–682

    CAS  Google Scholar 

  48. Nunziata V et al (1989) Cutaneous lichen amyloidosis associated with multiple endocrine neoplasia type 2A. Henry Ford Hosp Med J 37(3–4):144–146

    PubMed  CAS  Google Scholar 

  49. Verga U et al (2003) Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 59(2):156–161

    CAS  Google Scholar 

  50. Verga U, Beck-Peccoz P, Cambiaghi S (2002) Cutaneous lichen amyloidosis in multiple endocrine neoplasia type 2A. Thyroid 12(12):1149

    PubMed  Google Scholar 

  51. Amiel J et al (2008) Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet 45(1):1–14

    PubMed  CAS  Google Scholar 

  52. Mulligan LM, Ponder BA (1995) Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 80(7):1989–1995

    PubMed  CAS  Google Scholar 

  53. Arighi E et al (2004) Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung’s disease. Mol Endocrinol 18(4):1004–1017

    PubMed  CAS  Google Scholar 

  54. O’Riordain DS et al (1994) Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116(6):1017–1023

    PubMed  Google Scholar 

  55. Wray CJ et al (2008) Failure to recognize multiple endocrine neoplasia 2B: more common than we think? Ann Surg Oncol 15(1):293–301

    PubMed  Google Scholar 

  56. Gagel RF et al (1988) The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318(8):478–484

    PubMed  CAS  Google Scholar 

  57. Lips CJ et al (1994) Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331(13):828–835

    PubMed  CAS  Google Scholar 

  58. Machens A (2004) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 350(9):943

    PubMed  CAS  Google Scholar 

  59. Machens A, Dralle H (2008) Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf) 69(1):81–87

    CAS  Google Scholar 

  60. Machens A, Dralle H (2009) Prophylactic thyroidectomy in RET carriers at risk for hereditary medullary thyroid cancer. Thyroid 19(6):551–554

    PubMed  Google Scholar 

  61. Wermer P (1954) Genetic aspects of adenomatosis of endocrine glands. Am J Med 16(3):363–371

    PubMed  CAS  Google Scholar 

  62. Chandrasekharappa SC et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276(5311):404–407

    PubMed  CAS  Google Scholar 

  63. Yokoyama A et al (2004) Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 24(13):5639–5649

    PubMed  CAS  Google Scholar 

  64. Yan J et al (2006) Cdx4 and menin co-regulate Hoxa9 expression in hematopoietic cells. PLoS ONE 1:e47

    PubMed  Google Scholar 

  65. Karnik SK et al (2005) Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 102(41): 14659–14664

    PubMed  CAS  Google Scholar 

  66. Bertolino P et al (2003) Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech Dev 120(5):549–560

    PubMed  CAS  Google Scholar 

  67. Crabtree JS et al (2001) A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 98(3):1118–1123

    PubMed  CAS  Google Scholar 

  68. Loffler KA et al (2007) Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1. Int J Cancer 120(2): 259–267

    PubMed  CAS  Google Scholar 

  69. Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29(1):22–32

    PubMed  CAS  Google Scholar 

  70. Sato K et al (2000) Somatic mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in patients with sporadic, nonfamilial primary hyperparathyroidism. Surgery 127(3):337–341

    PubMed  CAS  Google Scholar 

  71. Haven CJ et al (2007) Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 67(3):370–376, 67

    CAS  Google Scholar 

  72. Machens A et al (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67(4): 613–622

    Google Scholar 

  73. Agarwal SK, Mateo CM, Marx SJ (2009) Rare germline mutations in cyclin-dependent kinase inhibitor genes in MEN1 and related states. J Clin Endocrinol Metab 94(5):1826–1834

    PubMed  CAS  Google Scholar 

  74. Marx SJ et al (1991) Heterogeneous size of the parathyroid glands in familial multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 35(6):521–526

    CAS  Google Scholar 

  75. Agha A et al (2007) Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J Endocrinol Invest 30(2):145–149

    PubMed  CAS  Google Scholar 

  76. Akerstrom G, Malmaeus J, Bergstrom R (1984) Surgical anatomy of human parathyroid glands. Surgery 95(1):14–21

    PubMed  CAS  Google Scholar 

  77. Rizzoli R, Green J 3rd, Marx SJ (1985) Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium levels after parathyroidectomy. Am J Med 78(3):467–474

    PubMed  CAS  Google Scholar 

  78. Burgess JR et al (1998) The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 133(2):126–129

    PubMed  CAS  Google Scholar 

  79. Peacock M et al (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90(1):135–141

    PubMed  CAS  Google Scholar 

  80. Falchetti A et al (2008) A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab 4(6):351–357

    PubMed  Google Scholar 

  81. D’Souza-Li L et al (2002) Identification and functional characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. J Clin Endocrinol Metab 87(3):1309–1318

    PubMed  Google Scholar 

  82. Hannan FM et al (2008) Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab 4(1):53–58

    PubMed  CAS  Google Scholar 

  83. Perren A et al (2007) Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 92(3):1118–1128

    PubMed  CAS  Google Scholar 

  84. Skogseid B et al (1987) A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience. J Clin Endocrinol Metab 64(6):1233–1240

    PubMed  CAS  Google Scholar 

  85. Yim JH et al (1998) Prospective study of the utility of somatostatin-receptor scintigraphy in the evaluation of patients with multiple endocrine neoplasia type 1. Surgery 124(6):1037–1042

    PubMed  CAS  Google Scholar 

  86. Triponez F et al (2006) Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 30(5):654–662, discussion 663–664

    PubMed  Google Scholar 

  87. Fendrich V et al (2006) An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 244(6):845–851, discussion 852–853

    PubMed  Google Scholar 

  88. Berna MJ et al (2006) Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 85(6):331–364

    CAS  Google Scholar 

  89. Murugesan SV, Varro A, Pritchard DM (2009) Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 29(10):1055–1068

    PubMed  CAS  Google Scholar 

  90. Pipeleers-Marichal M et al (1990) Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 322(11):723–727

    PubMed  CAS  Google Scholar 

  91. Gibril F et al (2001) Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86(11): 5282–5293

    PubMed  CAS  Google Scholar 

  92. Doherty GM, Thompson NW (2003) Multiple endocrine neoplasia type 1: duodenopancreatic tumours. J Intern Med 253(6):590–598

    PubMed  CAS  Google Scholar 

  93. Cisco RM, Norton JA (2007) Surgery for gastrinoma. Adv Surg 41:165–176

    PubMed  Google Scholar 

  94. Jensen RT et al (2006) Gastrinoma (duodenal and pancreatic). Neuroendocrinology 84(3):173–182

    PubMed  CAS  Google Scholar 

  95. Ruszniewski P et al (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71(8):2624–2630

    PubMed  CAS  Google Scholar 

  96. von Schrenck T et al (1988) Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 94(6):1326–1334

    Google Scholar 

  97. Ruszniewski P et al (1991) [Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients]. Gastroenterol Clin Biol 15(5):393–398

    PubMed  CAS  Google Scholar 

  98. Kulke MH et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26(20):3403–3410

    PubMed  CAS  Google Scholar 

  99. Berna MJ et al (2008) A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 93(5):1582–1591

    PubMed  CAS  Google Scholar 

  100. Placzkowski KA et al (2009) Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 94(4):1069–1073

    PubMed  CAS  Google Scholar 

  101. Grant CS (2005) Insulinoma. Best Pract Res Clin Gastroenterol 19(5):783–798

    PubMed  CAS  Google Scholar 

  102. Service FJ et al (1991) Functioning insulinoma – incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 66(7):711–719

    PubMed  CAS  Google Scholar 

  103. Gill GV, Rauf O, MacFarlane IA (1997) Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 73(864):640–641

    PubMed  CAS  Google Scholar 

  104. Vezzosi D et al (2005) Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 152(5):757–767

    PubMed  CAS  Google Scholar 

  105. Kulke MH, Bergsland EK, Yao JC (2009) Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360(2):195–197

    PubMed  CAS  Google Scholar 

  106. Levy-Bohbot N et al (2004) Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 28(11):1075–1081

    PubMed  Google Scholar 

  107. Dralle H et al (2004) Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 28(12):1248–1260

    PubMed  Google Scholar 

  108. O’Toole D et al (2006) Rare functioning pancreatic endocrine tumors. Neuroendocrinology 84(3):189–195

    PubMed  Google Scholar 

  109. Triponez F et al (2006) Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 243(2):265–272

    PubMed  Google Scholar 

  110. Chanson P, Salenave S (2004) Diagnosis and treatment of pituitary adenomas. Minerva Endocrinol 29(4):241–275

    PubMed  CAS  Google Scholar 

  111. Verges B et al (2002) Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87(2):457–465

    PubMed  CAS  Google Scholar 

  112. Padberg B et al (1995) Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch 426(6):541–548

    PubMed  CAS  Google Scholar 

  113. Trouillas J et al (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32(4):534–543

    PubMed  Google Scholar 

  114. Rosai J, Higa E, Davie J (1972) Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association. Cancer 29(4):1075–1083

    PubMed  CAS  Google Scholar 

  115. Lee CH et al (1986) Carcinoid tumor of the pancreas causing the diarrheogenic syndrome: report of a case combined with multiple endocrine neoplasia, type I. Surgery 99(1):123–129

    PubMed  CAS  Google Scholar 

  116. Debelenko LV et al (1997) Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 6(13):2285–2290

    PubMed  CAS  Google Scholar 

  117. Ferolla P et al (2005) Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab 90(5):2603–2609

    PubMed  CAS  Google Scholar 

  118. Teh BT et al (1998) Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 228(1):99–105

    PubMed  CAS  Google Scholar 

  119. Barzon L et al (2001) Multiple endocrine neoplasia type 1 and adrenal lesions. J Urol 166(1):24–27

    PubMed  CAS  Google Scholar 

  120. Skogseid B et al (1992) Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 75(1):76–81

    PubMed  CAS  Google Scholar 

  121. Whitley SA et al (2008) The appearance of the adrenal glands on computed tomography in multiple endocrine neoplasia type 1. Eur J Endocrinol 159(6):819–824

    PubMed  CAS  Google Scholar 

  122. Waldmann J et al (2007) Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch Surg 392(4):437–443

    PubMed  CAS  Google Scholar 

  123. Darling TN et al (1997) Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 133(7):853–857

    PubMed  CAS  Google Scholar 

  124. Asgharian B et al (2004) Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 89(11):5328–5336

    PubMed  CAS  Google Scholar 

  125. Pack S et al (1998) Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN1 gene. J Invest Dermatol 110(4):438–440

    PubMed  CAS  Google Scholar 

  126. Kato H et al (1996) Multiple endocrine neoplasia type 1 associated with spinal ependymoma. Intern Med 35(4):285–289

    PubMed  CAS  Google Scholar 

  127. Doumith R et al (1982) Pituitary prolactinoma, adrenal aldosterone-producing adenomas, gastric schwannoma and colonic polyadenomas: a possible variant of multiple endocrine neoplasia (MEN) type I. Acta Endocrinol (Copenh) 100(2):189–195

    CAS  Google Scholar 

  128. Karges W et al (2003) Bi-allelic inactivation of the MEN1 tumor suppressor gene in human grade II astrocytoma. Cancer Lett 196(1):23–27

    PubMed  CAS  Google Scholar 

  129. Asgharian B et al (2004) Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 10(3):869–880

    PubMed  CAS  Google Scholar 

  130. McKeeby JL et al (2001) Multiple leiomyomas of the esophagus, lung, and uterus in multiple endocrine neoplasia type 1. Am J Pathol 159(3):1121–1127

    PubMed  CAS  Google Scholar 

  131. Pieterman CR et al (2009) Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf) 70(4):575–581

    CAS  Google Scholar 

  132. Agarwal SK et al (2004) Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 1014:189–198

    PubMed  CAS  Google Scholar 

  133. Tham E et al (2007) Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab 92(9):3389–3395

    PubMed  CAS  Google Scholar 

  134. Ellard S et al (2005) Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf) 62(2):169–175

    CAS  Google Scholar 

  135. Geerdink EA, Van der Luijt RB, Lips CJ (2003) Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 149(6):577–582

    PubMed  CAS  Google Scholar 

  136. Bertherat J et al (2009) Mutations in regulatory subunit type 1A of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 94(6):2085–2091

    PubMed  CAS  Google Scholar 

  137. Horvath A, Stratakis CA (2008) Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord 9(1):1–11

    PubMed  CAS  Google Scholar 

  138. Lietman SA, Schwindinger WF, Levine MA (2007) Genetic and molecular aspects of McCune-Albright syndrome. Pediatr Endocrinol Rev 4 Suppl 4:380–385

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Yariv J. Houvras

Authors
  1. Yariv J. Houvras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gilbert H. Daniels
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yariv J. Houvras .

Editor information

Editors and Affiliations

  1. Cancer Center and Gastrointestinal Unit, Harvard Medical School, Massachusetts General Hospital, Boston, 02114, USA

    Daniel C. Chung

  2. Cancer Center, Harvard Medical School and, Massachusetts General Hospital, Boston, 02114, USA

    Daniel A. Haber

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Houvras, Y.J., Daniels, G.H. (2010). Multiple Endocrine Neoplasia. In: Chung, D., Haber, D. (eds) Principles of Clinical Cancer Genetics. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-93846-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-93846-2_11

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-93844-8

  • Online ISBN: 978-0-387-93846-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation